iSpecimen Inc (ISPC) Quote

8k out. On February 19, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field as President of the Company, effective immediately. In connection with her appointment, Ms. Field resigned as a member of the Board, and Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.



Ms. Yang has also been appointed to serve on the Audit Committee and Nominating and Corporate Governance Committee of the Board, replacing Ms. Field. Additionally, the Board appointed Mr. Richard Paolone as Chair of the Board, replacing Ms. Field in this role. Mr. Robert Bradley Lim remains the Company’s Chief Executive Officer and a member of the Board.



The compensation arrangements for Ms. Field in connection with her appointment as President have not yet been determined. The Company will disclose the material terms of any such arrangements in an amendment to this Current Report on Form 8-K or in another applicable filing once finalized.



Ms. Yang is an Associate Attorney at Quill & Arrow LLP based in Los Angeles, California, where she specializes in consumer protection and product liability litigation. Previously, she served as In-House Counsel at Halo Collective Inc., overseeing regulatory compliance, corporate transactions, and litigation matters related to cannabis operations and intellectual property. Prior to that, Ms. Yang was a Provisional Licensed Lawyer at Di Li Law, PC, where she focused on trademark filings, oppositions, and intellectual property matters. Ms. Yang holds an LL.M. in International Comparative Law from UCLA School of Law and an LL.B. in International Economic Law from East China University of Political Science and Law. Her expertise in litigation, corporate governance, and data analytics further strengthens the Board’s oversight capabilities. There are no arrangements or understandings between Ms. Yang and any other person pursuant to which she was selected as a director, nor are there any related party transactions between the Company and Ms. Yang that would require disclosure under Item 404(a) of Regulation S-K.



The Board and management team remain focused on executing the Company’s objectives and do not anticipate any disruption to the Company’s operations as a result of these leadership changes.

ISPC...........................................https://stockcharts.com/h-sc/ui?s=ISPC&p=W&b=5&g=0&id=p86431144783#google_vignette

ISPC, new 52 week low

ISPC.....................................https://stockcharts.com/h-sc/ui?s=ISPC&p=W&b=5&g=0&id=p86431144783

🤑🤑🤑🚀

Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style pandemic. iSpecimen is a market leader in the biospecimen space and leverages its vast network of suppliers to procure specimens for the anticipated potential demand that may come with the need to study this disease and develop a vaccine to address it.

Human metapneumovirus (hMPV) is a virus which causes upper respiratory infections. While those infected with hMPV typically present with only mild symptoms, it can make some people very sick and cause death in the elderly, immunocompromised, and those with chronic conditions. There is currently no vaccine for hMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the virus.

With the devastation of COVID 5 years ago, there is concern in some areas that the virus could cause similar problems as it spreads in a very similar fashion through respiratory droplets from coughing or sneezing, close personal contact and touching contaminated surfaces before contacting the mouth, nose, or eyes. hMPV is very difficult to differentiate from COVID-19, flu, and respiratory syncytial virus (RSV), and unlike these viruses there is no vaccine for hMPV.

The potential demand for hMPV specimens continues to grow as hMPV remains a significant area of attention in the news and concern among the general population. The potential demand for a vaccine for this fast spreading disease highlights the critical need for reliable access to high-quality specimens. iSpecimen is poised to address this need through its strategic global partnerships with high value suppliers and streamlining of specimen procurement.

About iSpecimen

Yes, Watching it closely as we speak.  Low floater? Could move quick with a little volume

needs more volume 

Will this run?

ISPC............................................................................a/h

And yesterday she was down 25% so seems as though the day traders found her. 🙄

Some specimen volume $3.40 + 14%

It briefly shot up to $5:39 about 1 hour ago🤣

They sent it to $5 last month..$3.87 +'12% 

iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
Newsfile Corp.
Newsfile Corp
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request. Next Day Quotes are possible to implement only when the Company knows the supplier's data on their specific capabilities and pricing, as well as understands the customer's requirements.

Recognizing the need for timely access to high-quality biospecimens to advance life science research, iSpecimen had introduced NDQ to offer researchers and providers with swift and accurate sample pricing. From fresh whole blood and prescreened mutation-characterized blocks to an array of clinically collected remnant, banked and prospective biospecimens, most quotes are provided within a day of receiving the inquiry.

Since introducing the program in 2023 and the recently completed build of a search tool, quotes can be created within minutes. With this capability, the Company's sales mix has increasingly shifted towards NDQ. In November 2024, 30% of all sales opportunities were Next Day Quotes. Of all quotes that were generated in November 2024, 48% were Next Day Quotes. Meanwhile, the conversion rate was high for Next Day Quotes. 60% of all purchase orders were Next Day Quotes1.

Leslie Hoyt, Senior Vice President of Operations commented, "Our customers have responded enthusiastically to iSpecimen's Next Day Quote Program. For the first six months of the program, NDQ has consistently yielded strong results, driving an estimated 60% of sales. The data continue to show that if we quote within the next business day, we greatly increase the likelihood of receiving a signed purchase order. Current and future customers respond positively because time matters."

Ms. Hoyt further commented, "We continue to enhance our internal databases and search tools to proactively harvest data, ensuring the viability of Next day Quote program while increasing the frequency with which Next Day Quotes are possible. This offering accelerates our operational timeline and the customer decision journey. Ultimately next day quotes allow researchers and providers to focus on what matters most, and iSpecimen to be a valuable service provider for all customers."

ISPC BLOWING UP

ISPC: I'm laughing at my OWN post back then!! (I should be doing stand-up in LA.)

Still 600k
Floater at $5.10 will the hedgies hit it more or is it done 

They claim more specimens to be delivered more revenue $5,59 + 25% 

PRESSURE BUILDING

ISPC POST SPLITER WANTS TO GO

ISPC 9.08 + 102%

Careful ..$4.11 offering
iSpecimen Inc.
We are offering on a best-efforts basis up to 1,216,545 shares of our common stock, par value $0.0001 per share (the “Shares”) at an assumed public offering price of $4.11 per share, which was the reported closing price of our common stock on the Nasdaq Capital Market (“Nasdaq”), on October 15, 2024.
We are also offering to each purchaser of Shares that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding shares of common stock immediately following the consummation of this offering the opportunity to purchase one Pre-Funded Warrant (in lieu of one share of common stock) (each a “Pre-Funded Warrant”). A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one share of common stock. The purchase price of each Pre-Funded Warrant will be equal to the price per Share, minus $0.0001, and the remaining exercise price of each Pre-Funded Warrant will equal $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Warrant we sell (without regard to any limitation on exercise set forth therein), the number of Shares we are offering will be decreased on a one-for-one basis.
We are registering the Shares and the shares of common stock issuable from time to time upon the exercise of the Pre-Funded Warrants hereby.
Our common stock is listed on Nasdaq under the symbol “ISPC”. On October 15, 2024, the reported closing price of our common stock was $4.11 per share. There is no established public trading market for the Pre-Funded Warrants. We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited.
The public offering price for the Shares in this offering will be determined at the time of pricing and may be at a discount to the then current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price. The final public offering price will be determined through negotiation between us and the investors based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience of our executive officers and the general condition of the securities markets at the time of this offering.
The Shares and Pre-Funded Warrants, if any, will be offered at a fixed price and are expected to be issued in a single closing. We expect this offering to be completed not later than two business days following the effective date of the registration statement of which this prospectus forms a part (the “Registration Statement”), and we will deliver all securities to be issued in connection with this offering delivery versus payment/receipt versus payment upon receipt of investor funds received by us. Accordingly, neither we nor WestPark Capital, Inc., whom we have engaged as the exclusive placement agent for this offering (“WestPark” or the “Placement
TABLE OF CONTENTS
Agent”) have made any arrangements to place investor funds in an escrow account or trust account since the Placement Agent will not receive investor funds in connection with the sale of the securities offered hereunder.
We have engaged WestPark as our exclusive placement agent to use its reasonable best efforts to solicit offers to purchase our securities in this offering. The Placement Agent is not purchasing or selling any of the securities we are offering and is not required to arrange for the purchase or sale of any specific number or dollar amount of the securities. Because there is no minimum offering amount required as a condition to closing in this offering the actual public offering amount, Placement Agent’s fee, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above and throughout this prospectus. We have agreed to pay the Placement Agent the Placement Agent fees set forth in the table below. See “Plan of Distribution” in this prospectus for more information.
? ? ?
Per Share
? ?
Total(2)
?
Public Offering Price
? ? ? $ ? ? ? ? $ ? ?
Placement Agent fees(1)
? ? ? $ ? ? ? ? $ ? ?
Proceeds, before expenses, to us
? ? ? $ ????? ? ? ? ? $ ????? ? ?
?
(1)
In connection with this offering, we have agreed to pay to WestPark as placement agent a cash fee equal to 4% of the gross proceeds received by us in the offering. We have also agreed to reimburse WestPark for all expenses related to the offering up to $[ ] for reimbursement of legal expenses and other out-of-pocket expenses in connection with its engagement as placement agent See “Plan of Distribution.”
?
(2)
Assumes investors purchase only Shares and no Pre-Funded Warrants in this offering.
?
Investing in our securities involves a high degree of risk. See the section entitled “Risk Factors” beginning on page 16 of the prospectus. You should carefully consider these risk factors, as well as the information contained in this prospectus before you invest.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
WestPark Capital, Inc.
The date of this prospectus is ???????? ??, 2024
TABLE OF CONTENTS?

TABLE OF CONTENTS
? ? ?
Page
?
ABOUT THIS PROSPECTUS
? ? ? ? ii ? ?
PROSPECTUS SUMMARY
? ? ? ? 1 ? ?
THE OFFERING
? ? ? ? 13 ? ?
SUMMARY FINANCIAL DATA
? ? ? ? 15 ? ?
RISK FACTORS
? ? ? ? 16 ? ?
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
? ? ? ? 42 ? ?
USE OF PROCEEDS
? ? ? ? 43 ? ?
CAPITALIZATION
? ? ? ? 44 ? ?
MANAGEMENT
? ? ? ? 46 ? ?
DESCRIPTION OF OUR SECURITIES
? ? ? ? 52 ? ?
PLAN OF DISTRIBUTION
? ? ? ? 57 ? ?
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS
? ? ? ? 60 ? ?
LEGAL MATTERS
? ? ? ? 65 ? ?
EXPERTS
? ? ? ? 65 ? ?
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
? ? ? ? 65 ? ?
WHERE YOU CAN FIND MORE INFORMATION
? ? ? ? 66 ? ?
This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See “Risk Factors” and “Special Note Regarding Forward-Looking Statements.”

ISPC $8.15 +70%

$6 to 2.50 to 7 bucks yeah ok

LOL

EXIT THAT TOP....

holding until tomorrow 10$+ potential

POST SPLITS BLOWING UP LIKE CRAZY

ISPC READY TO GO...AFTER HOURS PLAY OF THE DAY

Oink oink

ISPC MICRO FLOAT

ISPC...NEXT GLMD

ISPC BLOWING UP

ISPC..THERE IT GOES

ISPC...FIRST MAGNET UP AND THEN THE SECOND MAGNET AT 5.90 NEXT

ISPC HERE WE GO

ISPC HERE WE GO....MAGNET 5.46

ISPC COME ON GIVE US ANOTHER GLMD

ISPC NEXT ONE TO BEAST....LOW FLOAT MONSTER

LOW FLOAT MONSTER

ISPC HERE WE GO

ISPC POST RS 580K FLOAT

ISCP...................https://stockcharts.com/h-sc/ui?s=ISCP&p=W&b=5&g=0&id=p86431144783

ISPC...55s clearing here on Volume...🥳

ISPC: Now that was a rather JADED, CYNICAL, commentary on 'Wall Street' generally, Dude!! (He can't even SEE my posts. By the way, I'm now HALF-WAY through Monk's Nobel-Prize-winning treatise entitled, "American Cars of 1958". Monk's book also comes with a CD, which shows Monk & Family test-driving Monk's patented. "Electro-Hydrogen-Fuel-Cell-Aero-Hybrid" car prototype; see below!!)

ISPC: Well now, this one is quite a 'SPECIMEN' here in the Post-M today, Peeps. (No pun intended.)

Sooner or later the sun shines on every dog’s ass

She found some new sneakers

next in line